$80M Payday for Synta

GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy